Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz PharmaceuticalsJAZZ +4.00%73 PE Ratio (TTM) is 18.04 as of Aug. 04, 2026, which is 11% below its 10-year median of 20.17. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 270 Biotechnology companies, Jazz Pharmaceuticals ranks worse than 370370% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-04), Jazz Pharmaceuticals's share price is
$261.62.
Jazz Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $14.50. Therefore, Jazz Pharmaceuticals's PE Ratio (TTM) for today is 18.04.
The historical rank and industry rank for Jazz Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
JAZZ'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss Med: 20.17 Max: 193.67
Current: 18.04
During the past 13 years, the highest PE Ratio (TTM) of Jazz Pharmaceuticals was 193.67. The lowest was 0.00. And the median was 20.17.
JAZZ's PE Ratio (TTM) is not ranked
in the Biotechnology industry.
Industry Median: 26.525
vs JAZZ: 18.04
During the past 12 months, Jazz Pharmaceuticals's average EPS without NRIGrowth Rate was -63.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -14.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -2.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 3.40% per year.
During the past 13 years, Jazz Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 76.30% per year. The lowest was -67.40% per year. And the median was 11.15% per year.
Jazz Pharmaceuticals's EPS (Basic) for the
three
months ended in Jun. 2026 was $3.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $15.25.
Jazz Pharmaceuticals (NAS:JAZZ) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Jazz Pharmaceuticals PE Ratio (TTM) Related Terms
Jazz Pharmaceuticals PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAZZ vs BBIO, ASND, EXEL: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Jazz Pharmaceuticals's Share Price of today is $261.62.
Jazz Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Jazz Pharmaceuticals (JAZZ) has a PE Ratio (TTM) of 18.04 as of Aug. 04, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Jazz Pharmaceuticals and its competitors. This is 11% below median its historical median of 20.17. According to the industry distribution chart, Jazz Pharmaceuticals ranks #999999 out of 270 companies in the Biotechnology industry.
Is Jazz Pharmaceuticals' PE Ratio (TTM) too high?
Jazz Pharmaceuticals' current PE Ratio (TTM) of 18.04 is 11% below median its 10-year median of 20.17. The Biotechnology industry median PE Ratio (TTM) is 26.53. Jazz Pharmaceuticals' value of 18.04 is 32% below this industry median. Based on the distribution chart, Jazz Pharmaceuticals ranks #999999 out of 270 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' PE Ratio (TTM) compare to BBIO and ASND?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #999999 out of 270 companies for PE Ratio (TTM). This places Jazz Pharmaceuticals in the lower half of its industry. The industry median PE Ratio (TTM) is 26.53. Jazz Pharmaceuticals' value of 18.04 is 32% below this benchmark. While the company's 10-year median is 20.17 vs. the industry median of 26.53, Jazz Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 26.53, based on 270 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jazz Pharmaceuticals's current PE Ratio (TTM) of 18.04 is 32% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 26.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current PE Ratio (TTM) is 18.04, which is 11% below median its own 10-year median of 20.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.30, compared to a current price of $261.62 — trading 74.1% above its estimated fair value. The current PE Ratio (TTM) is 18.04, which is 11% below median its 10-year median of 20.17 and 32% below the Biotechnology industry median of 26.53. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current PE Ratio (TTM) is 18.04 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of $261.62 is trading 74.1% above its estimated GF Value™ of $150.30.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for JAZZ:
PE Ratio (TTM): 18.04 (11% below median its 10-year median of 20.17)
GF Value™: $150.30 vs. price of $261.62 (74.1% above fair value)
Industry Position: 32% below the Biotechnology median (#999999 of 270)
No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for JAZZ
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAZZ has been successfully added to your 
